Materials and Methods

Cell culture and transient transfection
COS-7 (monkey kidney, fibroblast), HEK293 (human kidney, fibroblast) and CHO-K1 (Chinese hamster ovary, epithelial) cells purchased from ATCC (Manassas, VA) were cultured in DMEM (Hyclone Dulbecco's Modified Eagle's Medium, GE Healthcare, UK) containing 10% FBS (Hyclone fetal bovine serum, GE Healthcare, UK) and 1% PS, penicillin G and streptomycin (PAA, Austria) at 37˚C in 5% CO 2 atmosphere. Electroporation (Neon R Transfection system, Life Technologies, Carlsbad, CA) was used to introduce appropriative amounts of EGFR constructs and plasma membrane targeting sequence (PMT) tagged with enhanced green fluorescent protein (eGFP) or monomeric red fluorescent protein (mRFP) into the cells using manufacturer`s electroporation parameters for certain cell lines. The cells seeded on coverslips (30 mm in diameter; Lakeside, Monee, IL) submerged in DMEM with 10% FBS were kept in the incubator at 37˚C in 5% CO 2 atmosphere. After an overnight incubation, the transiently transfected cells were serum-starved for minimum 4 hours and incubated for 30 min with the following three inhibitors with the final concentrations of 2 mM for NaF, 10 mM for NaN 3 and 5 mM for 2-deoxy-D-glucose (all inhibitors from Sigma-Aldrich, St. Louis, MO). Inhibitors were used to avoid internalisation and endocytosis of EGFR. All experiments were carried out in the presence of these inhibitors, except ligand stimulation measurements. Control experiments were conducted to confirm that the inhibitors do not interfere in EGFR dynamics and have no influence on the FCCS results (Fig. S8) . Finally the coverslip with the cells was washed with PBS and mounted to an imaging chamber filled with 1 ml PBS containing the three inhibitors. Cholesterol depletion treatment as well as disruption of cytoskeleton was done with a final concentration of 3 mM and 3 µM methyl-β-cyclodextrin (mβCD) and Latrunculin (LAT-A) in serum-free media 1 ml PBS, respectively. Cells were stimulated by low (10ng/ml) and high dose (100 ng/ml) EGF.
Cloning of the construct EGFR (1706Q, V948R)-eGFP
The plasmid EGFR (1706Q, V948R) was a gift from Professor Tony Ng, King`s College London. Three PCR reactions have been conducted to get the insert EGFR (1706Q, V948R)-eGFP. In the first PCR, EGFR (1706Q, V948R) was amplified using DNA template EGFR (1706Q, V948R) and the forward primer 1 5'-3': (AgeI) AAAACCGGTATGCGACCCTCCGGGA and reverse primer 2 5'-3': AAATCCTCGCCCTTGCTCACCATACTTCCTCCTCCTGCTCCAATAAATTCA. The first PCR product contains EGFR (1706Q, V948R) and the protein linker (GGGS) with eGFP starting sequence. In the second PCR reaction, eGFP (linker and EGFR part) was amplified from the template PMT-eGFP with the following forward primer 3 5'-3': (underlined: protein linker GGGS) AAATGAATTTATTGGAGCAGGAGGAGGAAGTATGGTGAGCAAGGGCGAGGAGC and reverse primer 4 5'-3' (NotI) AAAGCGGCCGCTTACTTGTACAGCTCGTCCAT. In the last PCR, the PCR product EGFR (1706Q, V948R) and the EGFP were used as a template with the forward primer 1 AAAACCGGTATGCGACCCTCCGGGA and reverse primer 4 AAAGCGGCCGCTTACTTGTACAGCTCGTCCAT to construct the insert EGFR (1706Q, V948R)-eGFP. The final product was digested with AgeI, and NotI and purified by gel electrophoresis. The plasmid PMT-mRFP (vector bone GFP) were cut by AgeI and NotI to remove PMT-mRFP and purified by gel electrophoresis. In the last step, the vector bone and insert were ligated using T4 Ligase (Thermo Scientific, Waltham, MA) at 16°C overnight. Afterwards, the ligated product was transformed into DH-5α cells and amplified.
FIGURE S1. Concept of ligand-dependent and ligand-independent pathway of EGFR. In ligand-dependent model, EGFR exist as monomers and undergo dimerization in the presence of EGF ligand. Liganded EGFRs aggregate to clusters to enhance signalling. In contrast, in ligand-independent model EGFR is found as monomers and preformed dimers. In the presence of EGF, this receptors change their confirmation to liganded dimers and thus clusters. (E-F) q for mRFP-EGFR/EGFR-eGFP in CHO-K1 plotted against the receptor density/µm². No dependence of q on receptor density was observed within the range of expression levels probed. Experiments were performed on the apical and the basal membranes at 37°C. 
FIGURE S7. (A)
. In all the above described experiments, the cells were incubated for 30 minutes with internalisation inhibitors. To verify that the presence of inhibitors does not influence the measured complex fraction of EGFR in the plasma membrane, we repeated the SW-FCCS experiments in CHO-K1 cells at room temperature in the absence of the inhibitors. The obtained apparent complex fractions of 23% ± 5% (n=21, 5 cells) on the basal and 33% ± 4% (n=25, 3 cells) on the apical membrane are in good agreement with the data acquired in the inhibitor-treated cells, confirming that the inhibitors do not interfere with EGFR complex formation. Additionally, no significant internalization of EGFR was observed within the time frame of the measurements. q values of the positive control mRFP-EGFR-EGFR (black bar) and the experiment mRFP-EGFR/EGFR-eGFP (grey bar) without internalisation inhibitors added in basal and apical membranes are compared to a control group treated by the inhibitors.
FIGURE S8. (A)
Analysis of EGFR-EGFR interaction in one selected cell in the presence of EGF ligand (100 ng/ml). Around 33% of the receptors reside in a complex form (B) After 3 min EGF addition, the complex amount increases rapidly to ~63% (C) oligomerization of stimulated EGFR molecules (D) cross-correlation amount of 88% at 15 min Table S1 . different q values of EGFR complexes. ( 
